GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » JD Health International Inc (HKSE:06618) » Definitions » Research & Development

JD Health International (HKSE:06618) Research & Development : HK$1,342 Mil (TTM As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is JD Health International Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. JD Health International's Research & Development for the six months ended in Dec. 2023 was HK$667 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 was HK$1,342 Mil.

JD Health International Research & Development Historical Data

The historical data trend for JD Health International's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

JD Health International Research & Development Chart

JD Health International Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial 376.38 722.01 1,093.34 1,191.73 1,341.51

JD Health International Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 601.37 570.62 648.12 674.71 666.80

JD Health International Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$1,342 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

JD Health International  (HKSE:06618) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

JD Health International Research & Development Related Terms

Thank you for viewing the detailed overview of JD Health International's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

JD Health International (HKSE:06618) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » JD Health International Inc (HKSE:06618) » Definitions » Research & Development
Comparable Companies
HKSE:06078 HKSE:02273 HKSE:01951 HKSE:01515 HKSE:00708 HKSE:03309 HKSE:06639 HKSE:02373 HKSE:02138 HKSE:02219 HCA SAU:4013 SZSE:300015 XTER:FRE BKK:BDMS XKLS:5225 BSP:RDOR3 XTER:FME UHS CHE
Traded in Other Exchanges
JDHIY:USA JDHIF:USA 8ZN:Germany
Address
No. 20 Kechuang 11 Street, Block C, Building 2, Jingdong Headquarters, Economic and Technological Development Zone, Daxing District, Beijing, CHN, 101111
Website
https://ir.jdhealth.com
JD Health is the largest healthcare e-commerce platform in China in terms of revenue. The company offers pharmaceutical drugs and healthcare products on its platform, both as a marketplace that connects merchants to consumers and as a first-party, or 1P, direct retailer. It also offers online consultation from real life doctors and separately partners with offline pharmacies that can provide location-based 24/7 delivery as part of an omnichannel initiative to complement its core e-commerce business. Its closest competitors are Alibaba Health, Ping An Good Doctor, and Meituan for its e-commerce business. As of Dec. 31, 2022, the platform has 154.3 million active annual users and over 70,000 merchants. JD Health is 67.49% owned by its parent company, JD.com.

JD Health International (HKSE:06618) Headlines

No Headlines